Skip to main content
. Author manuscript; available in PMC: 2016 Apr 13.
Published in final edited form as: JAMA. 2015 Oct 13;314(14):1488–1497. doi: 10.1001/jama.2015.12160

TABLE 2.

Clinical characteristics of study patients by influenza infection and vaccination status

Controls -
non influenza
pneumonia
(n=2605)
Cases –
influenza
pneumonia
(n=162)
P value Non-vaccinated
(n=1973)
Vaccinated
(n=794)
P value
Comorbidities and risk factors
Need oxygen supplementation at home, % (n) 7% (190) 6% (10) 0.59 5% (96) 13% (104) <0.001
Adult BMI (kg/m2), median (IQR) 27.4 (23.0, 33.0) 27.9 (25.1, 34.7) 0.08 27.4 (23.1, 32.9) 27.7 (23.0, 33.4) 0.76
Children BMI categories 1.00 0.84
  Underweight 20% (149) 20% (8) 19% (115) 20% (42)
  Normal 55% (419) 54% (22) 55% (324) 56% (117)
  Overweight 11% (85) 12% (5) 11% (65) 12% (25)
  Obese 14% (108) 15% (6) 15% (88) 12% (26)
Smoking, % (n) 0.007 <0.001
  Non-smoking 68% (1773) 61% (99) 68% (1346) 66% (526)
  Current smoking 14% (374) 23% (38) 17% (327) 11% (85)
  Past smoking 18% (458) 15% (25) 15% (300) 23% (183)
  Unknown 4% (99) 6% (10) 4% (85) 3% (24)
Chronic conditions 62% (1628) 56% (91) 0.11 59% (1159) 71% (560) <0.001
  Asthma or Reactive Airway Disease 33% (852) 33% (53) 1.00 32% (635) 34% (270) 0.36
  Chronic Obstructive Pulmonary Disease (COPD) 11% (292) 11% (18) 0.97 9% (170) 18% (140) <0.001
  Congenital Heart Disease 3% (87) 0% (0) 0.02 3% (51) 5% (36) 0.008
  Coronary Artery Disease 14% (358) 15% (24) 0.70 11% (211) 22% (171) <0.001
  Heart failure 11% (279) 5% (8) 0.02 7% (145) 18% (142) <0.001
  Diabetes mellitus 13% (337) 12% (19) 0.66 12% (227) 16% (129) <0.001
  Blood Disorder (e.g. sickle cell disease) 7% (189) 5% (8) 0.27 6% (120) 10% (77) <0.001
  Chronic Kidney Disease 8% (221) 6% (9) 0.19 6% (125) 13% (105) <0.001
  Chronic Liver Disease 3% (82) 6% (9) 0.10 3% (60) 4% (31) 0.25
  Splenectomy 1% (31) 0% (0) 0.16 1% (16) 2% (15) 0.02
  Non-cancer immunosuppressive condition 9% (236) 11% (18) 0.38 7% (134) 13% (106) <0.001
  HIV 2% (43) 4% (6) 0.06 1% (25) 3% (24) <0.002
  Cancer 9% (230) 8% (13) 0.73 7% (131) 14% (112) <0.001
  Immunosuppression 15% (393) 17% (28) 0.45 7% (142) 14% (112) <0.001
  Seizure disorder 5% (137) 6% 10) 0.62 5% (95) 7% (52) 0.07
  Obstructive Sleep Apnea 3% (86) 2% (3) 0.31 2% (45) 6% (44) <0.001
  Cerebral Palsy 1% (35) 2% (3) 0.59 1% (22) 2% (16) 0.07
  Dementia 1% (24) 1% (1) 0.69 1% (14) 1% (11) 0.09
  Stroke 3% (72) 1% (2) 0.24 2% (45) 4% (29) 0.04
  Guillain-Barre Syndrome 0% (4) 1% (1) 0.18 0% (2) 0% (3) 0.12
  Scoliosis 1% (14) 1% (1) 0.89 1% (10) 1% (5) 0.69
  Down’s Syndrome 1% (38) 0% (0) 0.12 1% (18) 3% (20) <0.001
  Other Chromosomal Abnormality 1% (36) 1% (2) 0.88 1% (23) 2% (15) 0.14
  Currently on steroids 11% (289) 11% (18) 1.00 10% (192) 14% (115) <0.001
Influenza and vaccination status, and timing of admission
Verified influenza vaccination, % (n) 29% (766) 17% (28) 0.002 0% 100%
Influenza confirmed by RT-PCR, % (n) 0% 100% 7% (134) 4% (28) <0.001
Disease onset to admission, median days (IQR) 3 (2,7) 3 (2, 6) 0.78 3 (2, 7) 3 (2, 6) 0.51
Admission week in flu season, median (IQR) 20.0 (13.0, 31.0) 26.0 (18.0, 32.8) <0.001 18 (11, 29) 27 (19, 35) <0.001
Days from vaccination to admission, median (IQR) 108.5 (64.0, 163.0) 124.0 (90.2, 150.2) 0.52 109.5 (64.2, 162.8)
Days from season start to admission, median (IQR) 138 (84, 214) 180 (124, 224) <0.001 124 (76, 198) 184 (127, 240) <0.001

Footnote: Immunosuppression included non-cancer immunosuppressive conditions, cancer (other than skin cancer) and HIV infection with CD4 count ≥200/mm3; chronic conditions encompass medical conditions associated with influenza-associated complications including cardiopulmonary disease, diabetes mellitus, blood disorders, chronic liver/kidney disease, immunosuppressive conditions (including cancer), and neuromuscular diseases. BMI categories for children were determined per CDC guidelines: Underweight (<5th BMI-for-age percentile), Normal (5th – <85th percentile), Overweight (85th – <95th percentile), and Obese (>=95th percentile). Additional information on the characteristics of the study population is available in supplementary tables 2S and 3S.